Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S Jokiranta
SAT0152 Real-Life Infliximab and Adalimumab Trough Level and Anti-Drug Antibody Measurements in Rheumatology: The Finnish Experience
Related publications
Infliximab (Anti–Tumor Necrosis Factor Α Antibody)
Archives of Dermatology
Detection of Anti-Infliximab Antibodies Is Impacted by Antibody Titer, Infliximab Level and IgG4 Antibodies: A Systematic Comparison of Three Different Assays
Therapeutic Advances in Gastroenterology
Gastroenterology
Infliximab and Adalimumab Drug Levels in Crohn's Disease: Contrasting Associations With Disease Activity and Influencing Factors
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Infliximab Versus Adalimumab in Patients With Biologic-Naïve Crohn’s Disease: Is the Difference Real?
Digestive Diseases and Sciences
Physiology
Gastroenterology
Editorial: Variability in Adalimumab Trough and Peak Serum Concentrations
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Suppression of Anti-Drug Antibodies to Infliximab or Adalimumab With the Addition of an Immunomodulator in Patients With Inflammatory Bowel Disease
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Editorial: Infliximab Trough Cut-Off for Perianal Crohn's Disease - Another Piece of the Therapeutic Drug Monitoring-Guided Infliximab Dosing Puzzle
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Editorial: Variability in Adalimumab Trough and Peak Serum Concentrations - Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection
Gastroenterology
Hepatology
Gastroenterology
